antiplatelet therapy, peripheral transluminal angioplasty
Conditions
Interventions
Intervention is comparing dualtherapy aspirin (80mg)/clopidogrel (75mg) to ticagrelor (90mg) and the current practice aspirin 80mg.
Sponsors
Antonius Hospital Nieuwegein, Medisch Centrum Alkmaar.
Eligibility
Inclusion criteria
Inclusion criteria: All patients presented for percutaneous endovascular intervention are eligable for inclusion. Inclusion criteria: (1) lesions to the iliac, femoropopliteal and below the knee (BTK) arteries; (2) eligibility of lesions for percutaneous transluminal angioplasty (PTA) or recanalization with or without additional stenting (ST), (3) all TASC lesions [16]; (4) all Rutherford (1-6) classes.
Exclusion criteria
Exclusion criteria: Exclusion criteria are patients with reported intolerance or hypersensitivity for the study medications, the use of anticoagulant therapy (coumarin derivatives; acenocoumarol / fenprocoumon / warfarin), the use of non-steroidal anti-inflammatory drugs in the two weeks prior to the venapuncture to determine eventual aspirin resistance, a history of platelet/bleeding abnormalities and a platelet count < 100x*10^6/dl.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the occurrence of the cardiovascular events myocardial infarction, in-stent thrombosis, re-intervention due to hemodynamic re-stenosis, the occurrence of cerebrovascular event (CVA or/and TIA), peripheral embolus and mortality after one year of follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint is occurrence of major and minor bleeding. According the TIMI criteria. | — |
Contacts
Public ContactC. Unlu
Medisch Centrum Alkmaar
Outcome results
None listed